Aptahem reports the FIH study on Apta-1 has been finalized

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, today announces that the report on the First in Human (FIH) study has been finalized. The final study report confirms the previous top line results. The study is now closed and reported to the authorities.

The top line results previously communicated from the study shows that Apta-1 has been well tolerated in the given doses. No serious side effects were seen and all participants fulfilled the study. In the additional analyzes that were performed during the study of Apta-1 highlighted some clinical markers which are important for understanding the mechanism of action and to support upcoming patient studies. The significance of these findings are being further investigated aided by pre-clinical studies.

CEO Mikael Lindstam comments:

”I am pleased to say that the FIH study with Apta-1 now has been finalized and reported as closed to the authorities. We are now looking forward to the next steps planning for a clinical phase 2 patient study.”

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company’s lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.

Tags: